The global omega 3 prescription drugs market size was estimated to be USD 2.81 billion in 2023 and is expected to reach at USD 7.50 billion by 2034 with a CAGR of 9.34% during the forecast period 2024-2034. Growing prevalence of cardiovascular diseases (CVDs), obesity, & hypertriglyceridemia, increasing concerns regarding the maintenance of cholesterol levels, surge in adoption of omega 3 drugs, increasing focus on development of novel drugs for the treatment of related disease conditions, and rising approval of plant-based omega-3 products by regulatory authorities are some of the key factors boosting the market growth.
Prescription omega-3 medications reduce the quantity of triglycerides, which are lipid-like substances, in the bloodstream and elevate the levels of beneficial cholesterol (HDL) within the body. Omega-3 drugs or fatty acids are essential nutrients derived from dietary sources (or supplements) that play a crucial role in the formation and upkeep of a healthy body, including the construction of cell membranes. Hence, rising approval of plant-based omega-3 products by regulatory authorities is predicted to boost the market growth during the forecast period. For instance, in October 2022, The European Commission has granted approval for DSM's plant-based omega-3 offerings, allowing their use as alternatives for both fish and animal-based products across the European Union. DSM asserts that these products improve the nutritional characteristics of plant-based foods and facilitate the creation of animal-derived fish substitutes that closely resemble existing fish products. This omega-3 supplement offers a way to enrich the nutritional value of items without negatively impacting the marine ecosystem.
By drug, vascepa was the highest revenue-grossing segment in the global omega 3 prescription drugs market in 2023 owing to the increasing adoption of Vascepa, growing levels of triglycerides and rising approvals of novel drugs by regulatory bodies. Additionally, Lovaza is predicted to grow at fastest CAGR during the forecast period owing to the rising adoption of Lovaza within the target population, growing regulatory approvals, and increasing launch of new products. For instance, In November 2022, Orlo Nutrition has unveiled a DHA Starter Kit and a supplement containing algal omega-3 to promote the well-being of various bodily systems, including the heart, brain, and joints.
By application, hypertriglyceridemia was the highest revenue-grossing segment in the global omega 3 prescription drugs market in 2023 owing to the rising prevalence of hypertriglyceridemia, surge in number of approvals of omega-3 fatty acid prescription products, and rising collaborations within market players. Additionally, Others is predicted to grow at fastest CAGR during the forecast period owing to the growing awareness level among the population regarding healthy living, increasing adoption of omega 3 prescription drugs, and rising research & development activities. For instance, in June 2023, A recent study conducted by the Harvard T.H. Chan School of Public Health suggests that the intake of omega-3 fatty acids, specifically alpha-linolenic acid (ALA) found in foods like flaxseeds, walnuts, and certain oils such as canola and soybean oils, might potentially decelerate the advancement of amyotrophic lateral sclerosis (ALS) in patients.
By distribution channel, retail pharmacy was the highest revenue-grossing segment in the global omega 3 prescription drugs market in 2023 owing to the presence of qualified pharmacists who provide patients with a superior level of service and attention than internet pharmacies, surge in awareness among the population regarding the product & easy access to Rx products from the retail pharmacy, and increasing partnerships & collaborations within market players. For instance, in June 2023, Nordic Naturals, a specialist in omega-3 formulas based in the United States, has collaborated with more than 2,500 Walmart stores with the objective of expanding the availability of its supplements to a broader customer base. Additionally, hospital pharmacy is predicted to grow at fastest CAGR during the forecast period owing to the availability of skilled medical professionals who strive to minimize prescription mistake and provide fast access to medications, and surge in strategic initiatives by major market players.
North America region is anticipated for the highest revenue share during the forecast period owing to the surge in prevalence of chronic diseases such as obesity & hypertriglyceridemia, rising demand for omega-3 drugs, growing launch of new products, increasing approvals by regulatory bodies, and surge in collaborations within leading market players. For instance, In September 2023, Nordic Naturals is introducing its Ultimate Omega and Algae Omega supplements to Sam's Club outlets across the United States. This partnership is another step forward in Nordic Naturals' mission to make omega-3 supplements easily attainable and cost-effective for a broader audience, as well as to assist people in achieving their goal of improved health. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the increasing concerns related to lowering triglyceride levels among the population, growing research & development activities for the development of plant-based omega 3 drugs, and rising demand for omega 3 products among population within the region. For instance, in November 2022, In Asia, South Korea, India, and Japan emerged as the top three markets for the highest volume of newly introduced omega-3 products, as indicated by a recent report released by the Global Organisation for EPA and DHA Omega3s (GOED).
Prescription omega-3 medications reduce the quantity of triglycerides, which are lipid-like substances, in the bloodstream and elevate the levels of beneficial cholesterol (HDL) within the body. Omega-3 drugs or fatty acids are essential nutrients derived from dietary sources (or supplements) that play a crucial role in the formation and upkeep of a healthy body, including the construction of cell membranes. Hence, rising approval of plant-based omega-3 products by regulatory authorities is predicted to boost the market growth during the forecast period. For instance, in October 2022, The European Commission has granted approval for DSM's plant-based omega-3 offerings, allowing their use as alternatives for both fish and animal-based products across the European Union. DSM asserts that these products improve the nutritional characteristics of plant-based foods and facilitate the creation of animal-derived fish substitutes that closely resemble existing fish products. This omega-3 supplement offers a way to enrich the nutritional value of items without negatively impacting the marine ecosystem.
By drug, vascepa was the highest revenue-grossing segment in the global omega 3 prescription drugs market in 2023 owing to the increasing adoption of Vascepa, growing levels of triglycerides and rising approvals of novel drugs by regulatory bodies. Additionally, Lovaza is predicted to grow at fastest CAGR during the forecast period owing to the rising adoption of Lovaza within the target population, growing regulatory approvals, and increasing launch of new products. For instance, In November 2022, Orlo Nutrition has unveiled a DHA Starter Kit and a supplement containing algal omega-3 to promote the well-being of various bodily systems, including the heart, brain, and joints.
By application, hypertriglyceridemia was the highest revenue-grossing segment in the global omega 3 prescription drugs market in 2023 owing to the rising prevalence of hypertriglyceridemia, surge in number of approvals of omega-3 fatty acid prescription products, and rising collaborations within market players. Additionally, Others is predicted to grow at fastest CAGR during the forecast period owing to the growing awareness level among the population regarding healthy living, increasing adoption of omega 3 prescription drugs, and rising research & development activities. For instance, in June 2023, A recent study conducted by the Harvard T.H. Chan School of Public Health suggests that the intake of omega-3 fatty acids, specifically alpha-linolenic acid (ALA) found in foods like flaxseeds, walnuts, and certain oils such as canola and soybean oils, might potentially decelerate the advancement of amyotrophic lateral sclerosis (ALS) in patients.
By distribution channel, retail pharmacy was the highest revenue-grossing segment in the global omega 3 prescription drugs market in 2023 owing to the presence of qualified pharmacists who provide patients with a superior level of service and attention than internet pharmacies, surge in awareness among the population regarding the product & easy access to Rx products from the retail pharmacy, and increasing partnerships & collaborations within market players. For instance, in June 2023, Nordic Naturals, a specialist in omega-3 formulas based in the United States, has collaborated with more than 2,500 Walmart stores with the objective of expanding the availability of its supplements to a broader customer base. Additionally, hospital pharmacy is predicted to grow at fastest CAGR during the forecast period owing to the availability of skilled medical professionals who strive to minimize prescription mistake and provide fast access to medications, and surge in strategic initiatives by major market players.
North America region is anticipated for the highest revenue share during the forecast period owing to the surge in prevalence of chronic diseases such as obesity & hypertriglyceridemia, rising demand for omega-3 drugs, growing launch of new products, increasing approvals by regulatory bodies, and surge in collaborations within leading market players. For instance, In September 2023, Nordic Naturals is introducing its Ultimate Omega and Algae Omega supplements to Sam's Club outlets across the United States. This partnership is another step forward in Nordic Naturals' mission to make omega-3 supplements easily attainable and cost-effective for a broader audience, as well as to assist people in achieving their goal of improved health. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the increasing concerns related to lowering triglyceride levels among the population, growing research & development activities for the development of plant-based omega 3 drugs, and rising demand for omega 3 products among population within the region. For instance, in November 2022, In Asia, South Korea, India, and Japan emerged as the top three markets for the highest volume of newly introduced omega-3 products, as indicated by a recent report released by the Global Organisation for EPA and DHA Omega3s (GOED).
Segmentation: Omega 3 Prescription Drugs Market Report 2022 - 2033
Omega 3 Prescription Drugs Market Analysis & Forecast by Drug 2023 - 2034 (Revenue USD Bn)
- Lovaza
- Vascepa
- Others
Omega 3 Prescription Drugs Market Analysis & Forecast by Application 2023 - 2034 (Revenue USD Bn)
- Hypertriglyceridemia
- Others
Omega 3 Prescription Drugs Market Analysis & Forecast by Distribution Channel 2023 - 2034 (Revenue USD Bn)
- Online Pharmacy
- Hospital Pharmacy
- Retail Pharmacy
Omega 3 Prescription Drugs Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
North America
- U.S.
- Canada
Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Omega 3 Prescription Drugs Market: Drug Estimates & Trend Analysis
8. Omega 3 Prescription Drugs Market: Application Estimates & Trend Analysis
9. Omega 3 Prescription Drugs Market: Distribution Channel Estimates & Trend Analysis
10. Regional Market Analysis
11. North America Omega 3 Prescription Drugs Market
12. Europe Global Omega 3 Prescription Drugs Market
13. Asia Pacific Global Omega 3 Prescription Drugs Market
14. Latin America Global Omega 3 Prescription Drugs Market
15. MEA Global Omega 3 Prescription Drugs Market
16. Competitor Analysis
17. Company Profiles
Companies Mentioned
- GSK plc (GlaxoSmithKline plc)
- Abbott
- Hikma Pharmaceuticals PLC
- Woodward Pharma Services
- Amarin Pharmaceuticals Ireland Ltd.
- Nordic Naturals
- Camber Pharmaceuticals Inc.
- Dr. Reddy’s Laboratories Ltd.
- Viatris Inc.
- Grupo Ferrer Internacional
- S.A.
- Zydus Group
- Natrapharm Inc. (Patriot Pharmaceutical Corp.)
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 145 |
| Published | October 2023 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 2.81 Billion |
| Forecasted Market Value ( USD | $ 7.5 Billion |
| Compound Annual Growth Rate | 9.3% |
| Regions Covered | Global |
| No. of Companies Mentioned | 13 |
